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A prospective nonrandomised trial was performed in order to evaluate tumour control and toxicity of low-dose adjuvant
radiotherapy in stage I seminoma with treatment portals confined to the para-aortic lymph nodes. Between April 1991 and March
1994, 721 patients were enrolled for the trial by 48 centres in Germany. Patients with pure seminoma and no evidence of lymph
node involvement or distant metastases received 26Gy prophylactic limited para-aortic radiotherapy. Disease-free survival at 5 years
was the primary end point. With a median follow-up of 61 months, 675 patients with follow-up investigations were evaluable for this
analysis. Kaplan–Meier estimates of disease-free and disease-specific survival were 95.8% (95% CI: 94.2–97.4) and 99.6% (95% CI:
99.2–100%) at 5 years and 94.9% (95% CI: 92.5–97.4%) and 99.6% (95% CI: 99.2–100%) at 8 years, respectively. A total of 26
patients relapsed. All except two were salvaged from relapse. In all, 21 recurrences were located in infradiaphragmatic lymph nodes
without any ‘in-field’ relapse. Nausea and diarrhoea grade 3 were observed in 4.0 and 1.0% of the patients, respectively. Grade 3 late
effects have not been observed so far. The results of our trial lend further support to the concept of limited para-aortic irradiation as
the recently defined new standard of radiotherapy in stage I seminoma. There is no obvious compromise in disease-specific or
disease-free survival compared to more extensive hockey-stick portals, which were used as standard portals at the time this study was
initiated.
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The prognosis of clinical stage I testicular seminoma is favourable,
with cure rates after orchiectomy and adjuvant radiotherapy of
approximately 95% (Zagars and Babaian, 1987; Dosmann and
Zagars, 1993; Vallis et al, 1995; Bauman et al, 1998). Traditionally,
the target volume of radiotherapy comprises infradiaphragmatic
para-aortic and ipsilateral iliac lymph nodes (‘hockey-stick’
portals). Para-aortic lymph nodes are the primary site of testicular
lymphatic drainage as has been demonstrated by early lymphan-
giography (Busch et al, 1965) and surgical lymphadenectomy
studies (Mason et al, 1991). Thus, limitation of the treatment
portals of irradiation to the para-aortic lymphatics may be
sufficient for safe control of retroperitoneal micrometastases in
stage I seminoma. Omitting pelvic radiotherapy carries the
potential benefit of reducing scattered radiation to the contra-
lateral testis, thus minimising the risk of treatment-induced
infertility (Jacobsen et al, 1997). Furthermore, limitation of the
treatment portals may reduce gastrointestinal toxicity as well as the
risk of secondary malignancies after treatment (Travis et al, 1997).
In 1986, Willich et al (1986) reported promising results for
limited para-aortic radiotherapy in stage I seminoma. This report
encouraged us to initiate a prospective multicentre trial in order to
further evaluate the potential of small-volume para-aortic irradia-
tion. The aims of our study were to quantify acute side effects as
well as late toxicity of irradiation, and to identify the pattern of
recurrences after treatment in order to optimise radiotherapy
portal definition. Subsequent to the commencement of our study,
several small pilot series showed recurrence rates and an overall
survival (OS) comparable to the results obtained with conventional
hockey-stick treatment (Read and Johnston, 1993; Niewald et al,
1995; Kiricuta et al, 1996; Logue et al, 1998; Sultanem et al, 1998).
Finally, in 1999, a large randomised MRC trial was published
demonstrating that confinement of the treatment portals to the
para-aortic region did not adversely affect the overall relapse
rate compared to hockey-stick portals (Fossa et al, 1999). This
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ltrial therefore established para-aortic radiotherapy as the new
standard of irradiation for stage I seminoma. In 2001, yet
another randomised MRC trial (TE18/19) demonstrated that
reduction of the para-aortic radiation dose to 20Gy was safe
without an increase in relapse rates as compared to 30Gy (Jones
et al, 2001).
Interim results of the per protocol population of our trial have
been reported previously (Bamberg et al, 1999) lending further
evidence to the role of para-aortic radiotherapy as the new
standard of radiotherapy in stage I seminoma. We now present an
intention-to-treat analysis of the entire study population after a
median time to follow-up of 61 months.
PATIENTS AND METHODS
Patient selection and staging process
Patients with pure testicular seminoma in clinical stage I disease
according to the Royal Marsden classification system were eligible
for the trial (no evidence of metastases). High inguinal ablation of
the tumorous testicle was required in every patient. The staging
procedure comprised a computed tomography (CT) of abdomen
and pelvis, a chest CT or chest X-ray, and analysis of tumour
markers alpha-fetoprotein (AFP) and human chorionic gonado-
tropin (b-HCG) prior and subsequent to ablation of the testis.
During the first year of the study, only patients with negative
presurgical levels of b-HCG were admitted. During the second and
third year of the trial, patients with elevated b-HCG levels of up to
200IUl
 1 were admitted as well, once there was evidence that
initial b–HCG elevation did not adversely affect the prognosis of
the patients (Mirimanoff et al, 1993). Exclusion criteria were a
positive AFP level prior to orchiectomy, a history of prior
abdominal/pelvic radiotherapy or chemotherapy, withdrawal of
informed consent, concurrent severe diseases, or treatment with
cobalt-60 machines. All patients were asked for informed consent
according to the Declaration of Helsinki.
Radiotherapy
Margins of the treatment portals were defined according to the
following criteria. The upper field border was set to the cranial rim
of the 11th thoracic vertebra, and the lower field margin was
defined by the inferior border of the fourth lumbar vertebra.
Lateral field margins were defined by the ends of the lateral
vertebral processes, resulting in a width of the fields between 9 and
11cm. Radiation portals were assigned using treatment simulators
in all patients.
Radiotherapy was applied through ventro-dorsal opposing fields
with 4–20MV photons of linear accelerators. Both opposing fields
were treated daily for five times a week with a fraction of
2.0Gyday
 1 as specified in the ICRU 29 report for opposing fields.
A total dose of 26Gy was applied in 17 days. If treatment
interruptions of more than 3 days occurred, the total dose was
increased to 30Gy.
Protocol violations
Protocol violations were classified as major violations (MAV) if
they had either a potentially adverse effect on the therapeutic
efficacy of radiotherapy, or if they were apt to increase treatment-
related side effects (no chest imaging or no CT abdomen/pelvis for
staging, no AFP or elevated AFP prior to ablation, incorrect stage
assignment, dose prescription of less than 25Gy or more than
34Gy). Protocol violations were classified as minor violations
(MIV) if no negative effect on treatment outcome or toxicity of
irradiation was assumed.
Follow-up
Follow-up examinations were performed every 3 months for the
first 2 years after radiotherapy and every 6 months thereafter.
Clinical examination, analysis of AFP and b-HCG, chest X-ray, and
assessment of late toxicities were required at each visit. Computed
tomography scans of abdomen and pelvis were taken twice a year
for the first 2 years, and annually thereafter. Abdominal ultrasound
was performed in turn with abdomino-pelvic CT scans (twice a
year during the first 2 years, once a year after the second year).
End points
The primary end point of the study was relapse-free survival at 5
years. Since a potent salvage chemotherapy is available for
relapsing patients, disease-specific survival (DSS) was chosen as
a secondary end point with an expected survival of at least 95% at 5
years. Furthermore, acute and late gastrointestinal and cutaneous
toxicities (see below) were defined as secondary end points.
Monitoring of side effects
Acute and late side effects of treatment (gastrointestinal and
cutaneous/soft tissue effects) were recorded during radiotherapy
and at each follow-up visit using the EORTC/RTOG scores.
Data monitoring and data processing
The pathohistologic, diagnostic, therapeutic, and follow-up data
were recorded on specially prepared forms and entered into a
computerised database at the coordinating centre (Tu ¨bingen
University) using the study monitoring system of the Institute
for Medical Information Processing (IMI, Tu ¨bingen University).
After closing of the database for this analysis (31 December 2001),
all data were transferred to the IMI for further data processing.
The trial was designed as an observational study over a period of
3 years. With an expected population of 600 at 3 years, a one-sided
95% confidence interval for a single proportion using the large
sample normal approximation will extend 1.3% from an expected
proportion of 3.7%. Thus, a 3.7% crude relapse rate for the entire
study population with a one-sided 95% confidence limit extending
to 5% would ensure that a rate of 5% – considered to be the highest
acceptable relapse rate – would not be surpassed. Failure from
treatment was continuously monitored over the treatment period
and early termination of the study was planned once the critical
relapse rate was observed during the treatment period.
Continuous variables were described by use of statistical
characteristics (means, standard deviations). Discrete variables
are described as counts and percentages. Kaplan–Meier estimates
and their 95% confidence intervals were computed for disease-free
survival (DFS), OS, and DSS at 5 and 8 years after the end of
radiotherapy. For statistical analysis, the database was converted
into SAS files and the SAS system (SAS 6.11 for Windows) was
used.
RESULTS
Between April 1991 and March 1994, 721 patients were enrolled for
the study by 48 institutions (see Appendix A). There was no
follow-up information available in 43 patients. These patients were
excluded from the analysis as were another three patients once
informed consent had been withdrawn. Median time to follow-up
of the remaining study population of 675 patients was 61 months
(range 0.6–121 months). Median age of the patients was 34 years
(range 16–73). A right-sided tumour was observed in 51.9% of the
patients, 47.7% had a left-sided tumour, and three patients (0.4%)
presented with bilateral seminoma. The distribution by tumour
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lhistology and T stage is shown in Table 1. In all, 82 patients
(12.2%) presented with an elevated b-HCG prior to ablation testis.
Protocol violations
A total of 485 patients (71.9%) were staged and treated strictly per
protocol (PP), while 115 (17%) and 75 patients (11.1%) had major
or minor protocol violations, respectively. Median radiation dose
for PP, MAV, and MIV was 26Gy (range 25–34Gy).
Tumour control and survival
In all, 26 patients have relapsed from treatment (18 PP, four MAV,
and four MIV). Of 26 recurrences, 22 were located in infra-
diaphragmatic lymph nodes. There was one mediastinal and one
supraclavicular relapse. Three patients developed distant metas-
tases. A total of 24 patients were salvaged by chemotherapy or
irradiation (Table 2, Figure 1). There was no ‘in-field’ relapse
except for one patient who on review of the initial CT scans was
found to have stage IIB seminoma. This patient progressed rapidly
after radiotherapy, was submitted to lymphadenectomy, and died
from cerebral embolism after surgery. A second patient suffering
from retroperitoneal recurrence refused salvage chemotherapy and
died of progressive disease. This patient was part of the PP
population. In addition, there were four nonseminoma-related
deaths. On relapse, 11 patients (1.63%) had tumour involving the
ipsilateral pelvis. However, isolated ipsilateral recurrence was rare
with only four patients affected (0.59%). Median time to relapse
was 14 months (range 0–86 months). Disease-free survival for PP,
MAV, and MIV were 96.1% (95% CI: 94.2–97.9%), 95.8% (95% CI:
91.7–99.9%), and 94.1% (95% CI: 88.3–99.7%) at 5 years, and
94.9% (95% CI: 92.0–97.8%), 95.8% (95% CI: 91.7–99.9%), and
94.1% (95% CI: 88.3–99.7%) at 8 years, respectively. Disease-free
survival and DSS for the entire population were 95.8 (95% CI:
94.2–97.4%) and 99.6% (95% CI: 99.2–100%) at 5 years, and
94.9% (95% CI: 92.5–97.3%) and 99.6% (95% CI: 99.2–100%) at 8
years, respectively (Figure 2). There was no statistically significant
difference between the three study populations for DFS or DSS (log
rank P¼0.71). Overall survival at 5 and 8 years was 99.1% (95%
CI: 98.4–99.9%) and 98.6% (95% CI: 97.3–99.9%), respectively.
Acute and late toxicity
Maximum acute toxicity of radiotherapy was dominated by nausea
grade I, which was observed in 46.1% of all patients (Table 3).
Grade 2 and 3 nausea was documented in 6.7 and 4.0% of the
patients, respectively. Skin toxicity was mild with grade 1, 2, and 3
side effects in 5.0, 0.3, and 0%, respectively. Likewise, diarrhoea
was infrequent with grade 1, 2, and 3 toxicity in 9.6, 1.0, and 1.0%
of the patients. There were no grade 4 side effects. Furthermore,
there were no statistically significant differences in acute toxicity
between the PP, MAV, or MIV populations.
On follow-up, four patients (0.6%) exhibited slight hyperpig-
mentation in the former treatment field (grade 1), and one patient
(0.2%) developed telangiectasia (grade 2). A mild subcutaneous
fibrosis EORTC (grade 1) was documented in one patient (0.2%).
In all, 10 patients (1.5%) reported occasional diarrhoea (grade 1)
and one patient (0.2%) had occasional diarrhoea with slight
cramps (grade 2). No grade 3 or 4 late toxicity has been observed.
Secondary tumours
Secondary tumours were observed in 17 patients (2.5%). Among
these, there were seven contralateral testicular cancers and one
contralateral carcinoma in situ. Nontesticular tumours comprised
centroblastic–centrocytic lymphoma, acute leukaemia, meningio-
ma, glioblastoma, head-and-neck cancer, gastrointestinal cancers,
and nasal basalioma. Four patients died due to uncontrolled
secondary malignancies.
DISCUSSION
Adjuvant radiotherapy has been the standard treatment for stage I
seminoma for decades. However, optimal management of the
patients is still a matter of controversy (Milosevic et al, 1999;
Classen et al, 2001). In spite of high cure rates achieved with
adjuvant radiotherapy, efforts have been made to introduce
alternative treatment strategies that would potentially reduce
major side effects of irradiation. Among these, impairment of
fertility by scattered radiation to the contralateral testis (Jacobsen
et al, 1997), gastrointestinal morbidity (Fossa et al, 1989), and the
risk of radiation-induced malignancies (Travis et al, 1997) are of
major concern. In order to avoid these side effects, a policy of
‘watch and wait’ has been evaluated at some centres (Maase et al,
1993; Warde et al, 1997) applying treatment only to those patients
suffering from relapse. Other study groups have investigated the
role of single-agent carboplatin as adjuvant treatment (Oliver et al,
1994; Dieckmann et al, 2000).
Yet another strategy to limit side effects of adjuvant treatment is
to minimise the target volume of radiotherapy by confining the
treatment portals to the para-aortic lymph nodes, which have
previously been shown to be the site of primary lymphatic
drainage of the testicles (Busch et al, 1965). Our trial reported here
is the largest prospective study evaluating the role of limited para-
aortic radiotherapy in stage I seminoma in a nonrandomised
setting. The low relapse rate observed in our study compares
favourably to results of previously published pilot series using this
treatment schedule (Willich et al, 1986; Niewald et al, 1995;
Kiricuta et al, 1996; Logue et al, 1998; Sultanem et al, 1998). While
these reports were limited by mostly retrospective analysis of the
patients and small study populations, our trial now provides
profound evidence for the feasibility and safety of limited para-
aortic radiotherapy in stage I seminoma in a sufficiently large
number of patients.
There was no follow-up information available in 43 patients who
were consequently excluded from the analysis. Owing to the small
proportion of patients excluded, it is unlikely that this would have
had a relevant influence on the calculation of survival parameters
and the principle conclusion of our trial that para-aortic radio-
therapy yields excellent results with respect to tumour control.
The rate of ipsilateral iliac relapses observed in our patients was
low (1.63%). This rate is well in the range of 0–2.2% observed by
other authors for limited para-aortic treatment (Kiricuta et al,
1996; Logue et al, 1998; Sultanem et al, 1998). It can, however, be
speculated that inclusion of ipsilateral iliac lymph nodes into the
target volume might have prevented relapse from seminoma in
some of our patients. Yet, at the same time, routine treatment of
Table 1 Distribution of primary tumours by histology and T stage
according to 1987 TNM classification of UICC
Histology Patients n (%)
Classical seminoma 641 (95)
Spermatocytic seminoma 10 (1.5)
Anaplastic seminoma 19 (2.8)
No further subclassification 5 (0.7)
T stage Patients n (%)
1 565 (83.7)
2 94 (13.9)
3 14 (2.1)
4 0 (0)
Unknown 2 (0.30)
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lthe pelvis would have been of no value in more than 98% of the
patients merely contributing to treatment-related toxicity instead.
This finding of only a very small benefit from pelvic irradiation is
supported by a randomised MRC trial directly comparing para-
aortic treatment to conventional hockey-stick radiotherapy (Fossa
et al, 1999). The trial reported a significant but very small increase
in pelvic recurrences of 1.8% when omitting iliac treatment.
Any increase in the pelvic recurrence rate after para-aortic
treatment has to be weighted against the overall DFS in these
patients. When comparing the relapse rate of 5.1% observed in our
trial (including one patient with initial stage IIB seminoma) to
reported recurrence rates of 2–6% for conventional ‘hockey-stick’
irradiation (Zagars and Babaian, 1987; Vallis et al, 1995; Bauman
et al, 1998), there seems to be no obvious compromise in overall
tumour control by omitting pelvic radiotherapy. Finally, with a
disease-specific mortality of less than 1%, survival was not
compromised in our study. These findings are again supported
by the previously mentioned MRC trial, which could reliably
exclude an increase in the overall relapse rate of more than 4.6%
and a decrease in survival of more than 1.7% for patients treated
with limited para-aortic radiotherapy (Fossa et al, 1999).
Our study is limited by the nonrandomised trial design, and
conclusions drawn from this study might be considered to be
less compelling. However, it has recently been demonstrated that
well-designed observational trials do not systematically over-
estimate the magnitude of treatment effects as compared to
randomised studies (Benson and Hartz, 2000; Concato et al, 2000).
Therefore, with a large number of homogeneously managed
patients, our study provides sound evidence that omission of
pelvic treatment is safe without a clinically relevant increase in the
overall relapse rate.
Protocol violations observed in 28% of our patients are of major
concern, since nonadherence to protocol requirements might
impact on treatment outcome. However, neither DFS nor acute
Table 2 Recurrence from testicular cancer after adjuvant radiotherapy
No.
Primary
tumour
location
Time to
relapse
Location of
recurrent disease Histology of relapse Treatment for relapse Status Second relapse
1 Left 9 Liver, lung, iliac left Seminoma 4 PEI+IF-RT left iliac
36Gy
CR No
2 Left 25 Th 8–10 with
intraspinal tumour
growth
ND IF-RT 40.5Gy+2 PEB CR No
3 Right 11 C4–6 and cervical
lymph nodes
ND 4 PEB+IF-RT 30Gy CR No
4 Right 89 Vesicular seminalis
right
a
Seminoma 4  carboplatin, on local
relapse in vesicula seminalis:
pelvic RT to 26Gy and
prostatic boost to 30Gy
CR No
5 Left 28 Left supraclavicular
b Seminoma and lymphoma Mantle-field RT 30Gy CR No
6 Right 27 Mediastinal Seminoma 6 PEB CR No
7 Left 26 Left iliac+mediastinal ND 3 PEB+surgery CR No
8 Left 3 Left kidney hilum Seminoma Surgery Dead No
9 Left 28 Left iliac+left kidney
hilum
ND 4 PEB, 2 PEI, surgery
for residual lymphoma
CR No
10 Left 13 Right upper iliac
commune, bifurcation
Seminoma Surgery+3 PEB CR No
11 Left 47 Low para-aortic iliac left Seminoma Surgery+3 PEB CR No
12 Left 12 Left kidney hilum and
iliac commune left
Not known 4 PEB CR No
13 Right 19 Right inguinal Seminoma Surgery+IF-RT 26Gy CR No
14 Left 4 Left inguinal Seminoma IF-RT 30Gy CR No
15 Right 9 Iliac right, bifurcation ND 4 PEB CR No
16 Right 6 Right iliac Not known 3 PEI CR No
17 Left 6 Left iliac Not known 3 PEB CR No
18 Left 39 Left inguinal
c Seminoma Surgery+3 PEV CR No
19 Left 15 Bilateral inguinal/iliac Seminoma Surgery (inguinal left)+RT
bilateral iliac/inguinal and
left scrotal: 42Gy
CR 34 months after PD:
para-aortic/iliac and
mediastinal; CR after
4 CEB
20 Right 21 High iliac right and
para-aortic right
ND Refused salvage treatment Dead No
21 Right 1 Right kidney hilum ND 2 PEB CR No
22 Left 13 Iliac commune left/
external iliac
Seminoma Surgery+chemotherapy,
schedule unknown
CR No
23 Left 11 Left inguinal/iliac Seminoma Surgery+IF-RT 36Gy CR 40 months after PD:
inguinal left; CR after
surgery+2 PEB
24 Left 16 Iliac left/inguinal Seminoma 4 PEB+1 PEI CR No
25 Left 1 Iliac right ND 3 PEB CR No
26 Left 35 Left kidney hilum, para-
aortic
ND 4 PEI CR No
ND¼not done; CR¼complete remission; PEB¼ cisplatin, etoposide, bleomycin; PEI¼ cisplatin, etoposide, ifosfamide; PEV¼cisplatin, etoposide, vincristin; CEB¼carboplatin,
etoposide, bleomycin; IF-RT¼involved-field radiotherapy; RT¼radiotherapy; PD¼primary diagnosis.
aPatient suffered from second tumour (meningioma).
bRecurrence
combined with cc-cb-lymphoma.
cPrevious herniotomy.
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ltoxicity was significantly influenced by conservatively defined
major or minor protocol violations, respectively. This finding
indicates that protocol violations documented in our trial do in
fact not confound our results. They rather reflect some hetero-
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Figure 1 Locations of infradiaphragmatic recurrences. The numbers refer to Table 2.
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Figure 2 Kaplan–Meier curve for the entire study population.
Pts¼patients; DFS¼disease-free survival, OS¼overall survival.
Table 3 Maximum acute toxicity of radiotherapy assessed for skin,
nausea, and diarrhoea
EORTC/RTOG grade Skin Nausea Diarrhoea
0 94.3 42.8 88.0
1 5.0 46.1 9.6
2 0.3 6.7 1.0
3 0 4.0 1.0
40 0 0
Unknown 0.4 0.4 0.4
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lgeneity in treatment quality, which may be expected in any trial
with a large number of participating centres.
With four patients recurring with involvement of the ipsilateral
kidney hilum and another three patients failing near the lower field
border at high iliac commune lymph nodes, moderate extension of
the portals to cover these areas might have prevented relapse from
seminoma in some of our patients. In fact, field alignment in the
recent MRC trials (Fossa et al, 1999; Jones et al, 2001) included the
kidney hilum ipsilateral to the primary tumour and covered one
more lumbar vertebra including L5. This moderate extension of the
portals is not expected to increase significantly toxicity of radio-
therapy but rather bears the potential to further lower locoregional
relapse rates of irradiation. Based on the result from our trial, we
recommend to extend standard field margins to cover the fifth
lumbar vertebra and to include the ipsilateral kidney hilum.
Computed tomography scans of abdomen and pelvis for follow-
up were mandatory in our trial. However, the majority of patients
with infradiaphragmatic recurrence had relapse that involved the
pelvis. Therefore, the need for abdominal CT scans is questionable
since the detection rate of isolated abdominal recurrences was in
fact very low.
The radiation dose of 26Gy applied in our trial, although
somewhat lower than 30–35Gy recommended by other European
authors (Fossa et al, 1989, 1999; Kiricuta et al, 1996), is sufficient
for control of microscopic seminoma, since no true in-field
recurrence was observed. Furthermore, there is now convincing
evidence that a further dose reduction to 20Gy is safe without
compromise in tumour control as has recently been demonstrated
by MRC trials TE18/19 (Jones et al, 2001).
We observed a strikingly low incidence of acute toxicity. In
addition, no major late toxicity like duodenal ulcers, or gastro-
intestinal discomfort, which have been observed by others (Fossa
et al, 1989), was noted in our patients. Fossa et al (1999) reported a
considerably higher rate of acute grade 2 and 3 side effects of 14
and 11% nausea, respectively. The radiation dose used in their trial
was 30Gy as compared to 26Gy in our study. A further dose
reduction to 20Gy can therefore be expected to translate into an
even more favourable profile of toxicity (Jones et al, 2001) thus
beneficially impacting on the quality of life of the patients.
Furthermore, the shortened treatment schedule will possibly
reduce the days off work. These benefits of the reduced treatment
dose may ultimately lower the socioeconomic costs caused by stage
I seminoma. Finally, reducing the radiation dose to 20Gy may also
be beneficial with respect to the risk of radiation-induced
secondary malignancies. These are a serious concern in seminoma
patients, and a significant risk of radiation-induced tumours has
previously been demonstrated (Travis et al, 1997). A total of 17
patients in our series suffered from secondary tumours, and nine
of these were nontesticular events. Considering this low rate of
nontestis tumour events, there is no obvious excess of secondary
malignancies, but longer follow-up is warranted for a more reliable
assessment of the risk of secondary cancers in this cohort of
seminoma patients as the reported latency is some 10–15 years
(Travis et al, 1997).
To overcome potential disadvantages of adjuvant radiotherapy,
single-agent carboplatin chemotherapy has gained increasing
interest in recent years. Several small pilot studies demonstrated
low relapse rates in the range of 3–5% using 1–2 courses of
carboplatin (Oliver and Ong, 1996; Krege et al, 1997; Dieckmann
et al, 2000). The potential advantage of this treatment option may
be the reduced treatment time, treatment of micrometastasis
outside the strictly defined portals of radiotherapy, reduction in
the risk of secondary malignancies, and improvements in
treatment-related toxicities. However, equivalence of adjuvant
radiotherapy and carboplatin chemotherapy in terms of relapse
rates has yet to be demonstrated, and two randomised trials are
currently conducted by the MRC and the German Testicular
Cancer Study Group (GTCSG) to clarify this question. Yet another
potential alternative to adjuvant radiotherapy is the surveillance
strategy. The intention of this approach is to reserve active
treatment to those patients relapsing after primary orchidectomy
and to spare the majority of patients any potentially toxic adjuvant
treatment. Several study groups could demonstrate that the DSS of
the patients managed by surveillance is not compromised as
compared to radiotherapy. The rate of relapse is in the range of
14–19%, and the DSS approaches 100% (Horwich et al, 1992;
Maase et al, 1993; Oliver et al, 1994; Warde et al, 1997). In a pooled
analysis of the three largest surveillance protocols, the tumour size
(44cm) and tumour invasion of the rete testis were identified as
independent prognostic factors for relapse (Warde et al, 2002).
These risk factors may help to identify patients with a high or low
risk of relapse and may be beneficial for information of the patient
in the process of decision-making in adjuvant treatment. However,
a risk-adapted surveillance strategy using these factors has up to
date not prospectively been evaluated.
In conclusion, our trial provides further evidence in a large
study population with long-term follow-up that limited para-aortic
irradiation in stage I testicular seminoma is safe and feasible
yielding excellent cure rates at a very low rate of treatment-related
toxicity. In comparison to published data on conventional hockey-
stick treatment, the rate of recurrences is not increased. Those
patients suffering from relapse can be cured by systemic treatment
or radiotherapy. Judging from our trial and the previously
reported randomised study (Fossa et al, 1999), we consider limited
para-aortic treatment for stage I seminoma as the new standard of
radiotherapy (Krege et al, 2001) against which other potential
alternatives like surveillance or adjuvant carboplatin chemother-
apy have to be compared. We recommend standard field margins
extending from Th11 to the fifth lumbar vertebra and including the
ipsilateral kidney hilum.
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Appendix A
LIST OF PARTICIPATING CENTRES IN GERMANY
XRT Stadt- und Kreiskrankenhaus, Ansbach; XRT Klinikum,
Aschaffenburg; XRT Krankenhauszweckverband, Augsburg; XRT
Klinikum, Bamberg; XRT Klinikum, Bayreuth; XRT Charite ´,
Berlin; URO Klinikum am Urban, Berlin; XRT Klinikum Steglitz,
Berlin; XRT Johannes-Krankenhaus, Bielefeld; XRT St Agnes-
Hospital, Bocholt; XRT Sta ¨dt. Kliniken, Darmstadt; XRT Uni-
versita ¨tsklinikum, Dresden; XRT Klinikum, Duisburg; XRT Uni-
versita ¨tsklinikum, Du ¨sseldorf; XRT Universita ¨tsklinikum,
Erlangen; URO Marienhospital, Erwitte; XRT Universita ¨tsklini-
kum, Essen; XRT Krupp-Krankenhaus, Essen; XRT Krankenhaus
Nordwest, Frankfurt; XRT Universita ¨tsklinikum, Freiburg; URO
Klinikum, Fulda; XRT Krankenhaus am Eichert, Go ¨ppingen; XRT
Universita ¨tsklinikum, Go ¨ttingen; XRT Sta ¨dtisches Krankenhaus,
Gu ¨tersloh; XRT Allgemeines Krankenhaus, Hagen; XRT Universi-
ta ¨tsklinikum, Halle; URO Bundeswehrkrankenhaus, Hamburg;
XRT Universita ¨tsklinikum, Eppendorf, Hamburg; XRT Marien-
hospital, Hamm; XRT Universita ¨tsklinikum, Heidelberg; XRT
Sta ¨dtische Krankenanstalt, Heilbronn; XRT Sta ¨dtische Klinik,
Karlsruhe; XRT St Vincentius Krankenhaus, Karlsruhe; XRT
Universita ¨tsklinikum, Ko ¨ln; XRT Klinikum, Konstanz; XRT Sta ¨dt.
Krankenanstalten, Krefeld; XRT Universita ¨tsklinikum, Lu ¨beck;
XRT Klinikum, Ludwigsburg; URO Klinikum, Mannheim; XRT
Evangelisches Krankenhaus, Mu ¨lheim/Ruhr; XRT Klinikum
Nord, Nu ¨rnberg; XRT Kreiskrankenhaus, Offenburg; XRT
Sta ¨dt. Krankenhaus, Passau; XRT Winterberg-Krankenhaus,
Saarbru ¨cken; XRT Diakoniekrankenhaus, Schwa ¨bisch-Hall; XRT
Klinikum, Schwerin; XRT Katharinen Hospital, Stuttgart; XRT
Mutterhaus der Borroma ¨erinnen, Trier; XRT Universita ¨tsklinikum,
Tu ¨bingen.
XRT¼Department of Radiation Oncology; URO¼Department
of Urology.
Para-aortic radiotherapy for stage I seminoma
J Classen et al
2311
British Journal of Cancer (2004) 90(12), 2305–2311 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l